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The possible role of avoidable chemical
exposures in human breast cancer attracts
much public attention and has significant
public policy ramiﬁcations. Breast cancer is
the most commonly diagnosed malignancy
in women living in Canada, the United
States, and northern Europe. A generally
steady increase in incidence has been
recorded since the 1940s. It is now estimated
that one in nine women living in Canada
will develop this disease within their lifetime.
Although the mortality rate of breast cancer
has declined because of earlier detection and
improved therapy, the loss of lives remains
second only to lung cancer among malignan-
cies in women. In Canada, it is estimated
that this year over 19,200 new cases will be
diagnosed and more than 5,500 women will
die of breast cancer (1). 
The etiology of human breast cancer
remains largely unknown. Risk factors asso-
ciated with breast cancer can be grouped
into three broad determinants: family history
(hereditary) factors, hormonal and reproduc-
tive factors, and environmental (including
lifestyle) factors. A recent epidemiologic
analysis concluded that 73% of breast can-
cers are attributable to environmental factors
(2). Over 78% of breast cancer cases occur
in postmenopausal women. Late onset is
consistent with the long latency periods typi-
cally associated with chemical carcinogenesis
in humans.
In this review, we will discuss recent
research relevant to the possible environmen-
tal etiology of human breast cancer. First, we
consider genetic and hormonal factors that
influence breast cancer biology. Many of
these factors may also interact with environ-
mental exposures, for example, by affecting
the metabolism of environmental chemicals.
Subsequently, we consider several specific
classes of environmental chemicals that may
act to initiate human breast cancer. A particu-
lar focus of the review is the possible role of
environmental chemical mutagens. This
emphasis certainly reﬂects the authors’ own
interests, but we believe that the focus is con-
sistent with the renewed scientiﬁc attention to
this long-standing question. An international
scientiﬁc meeting on the topic of breast can-
cer and environmental mutagens was held
under the auspices of the Environmental
Mutagen Society, United States, and with
sponsorship by the National Institute of
Environmental Health Sciences, in September
2001 (Research Triangle Park, North
Carolina). The invited papers presented at
that meeting will appear in a forthcoming
issue of Environmental and Molecular
Mutagenesis (2002), and the interested reader
is directed to that publication for much
additional information.
Hormonal and Genetic Factors
in Breast Cancer
Estradiol binds with high afﬁnity to estrogen
receptor alpha. This binding induces DNA
synthesis, cell division, and production of
growth factors and progesterone receptor
proteins. Estrogens and progesterone are
essential for normal mammary gland devel-
opment and function, but their stimulation
of breast cell proliferation may be procar-
cinogenic. Many of the identiﬁed risk factors
for breast cancer can be explained by their
effects on lifetime exposure to estrogen and
other hormones (3). These effects include
both risk factors (increased exposure: early
menarche, nulliparity, late menopause, oral
contraceptive use, hormone replacement
therapy) and protective factors (decreased
exposure: full-term pregnancy at young age,
breast-feeding). Estrogens and progesterone
interact with speciﬁc receptor proteins in the
cell nucleus. Furthermore, estrogens can be
metabolically activated to cytotoxic and
genotoxic products (4).
Breast cancers develop through a series of
premalignant stages to invasive cancer accom-
panied by multiple steps of oncogene activa-
tion and tumor suppressor gene inactivation
(5). The HER-2/neu (c-erbB-2) protoonco-
gene is a member of the epidermal growth
factor receptor family. Overexpression of its
gene product, a transmembrane glycoprotein
with tyrosine kinase activity, has been
detected in 10–40% of human breast tumors
(6). This overexpression has been associated
with ineffective tamoxifen therapy (7). The
BCL-2 and related gene families regulate tis-
sue development and homeostasis. Two of
their protooncogene products, bcl-2 and bax,
have been identified as apoptosis-related
markers. In patients with breast cancer bcl-2
overexpression has been associated with a
better prognosis, whereas decreased bax
expression has been linked to poor clinical
outcome (8,9). 
The tumor suppressor gene p53 is recog-
nized as the most common somatically
mutated gene in human cancers (10). p53
protein participates in regulation of the cell
cycle, DNA repair, apoptosis, and other crit-
ical functions. It is estimated that p53 muta-
tions occur in 40% of sporadic breast
tumors (11). The p53 mutational spectrum
of breast cancers resembles that in lung can-
cer, suggesting that mutagenic xenobiotics
may be responsible (11,12). The presence of
certain p53 mutations can indicate poor
response to systemic therapy, adverse prog-
nosis for recurrence, and higher mortality in
patients with breast cancer (13,14). Other
tumor suppressor gene products implicated
in human breast cancer include Rb, cyclin-
dependent kinase inhibitors, and DNA-
mismatch repair proteins (15).
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Guelph, Ontario, CanadaHereditary factors are associated primarily
with early-onset premenopausal breast can-
cer. During the 1990s genetic analysis of
breast cancer–prone families identified the
BRCA1 and BRCA2 genes. Women with
mutations in either BRCA1 or BRCA2 (over
250 mutations have been identiﬁed) are at a
signiﬁcantly elevated lifetime risk (55–85%
compared with 12% for the general popula-
tion) for developing breast or ovarian cancer
(16). Approximately 5–10% of breast cancer
cases can be attributed to germline muta-
tions in BRCA1 or BRCA2. Recent evidence
suggests that BRCA1 and BRCA2 may have
important but distinct roles in sporadic
breast cancer (17,18). BRCA1 and BRCA2
encode multifunctional protein products
implicated in transcriptional regulation, cell
cycle control, apoptosis, and DNA-repair
pathways (19). The detection of the protein
products of the BRCA1 and BRCA2 genes in
milk fat globules also suggests a possible role
in lactation (20).
Polymorphisms of Drug-
Metabolizing Enzymes That
May Inﬂuence the Risk of
Breast Cancer
Polymorphisms have been identified in the
genes encoding many enzymes involved in
the bioactivation and detoxication of envi-
ronmental chemicals, dietary agents, and
endogenous steroids. A mutation may give
rise to a bioactivating enzyme with increased
activity or to a detoxifying enzyme with
decreased activity; either scenario could
increase susceptibility to mammary carcino-
genesis. Most of the major families of drug-
metabolizing enzymes have been examined
in this regard, including cytochrome
P450 (CYP), glutathione S-transferase
(GST), arylamine N-acetyltransferase (NAT),
catechol-O-methyltransferase (COMT), sul-
fotransferase (SULT), and uridine diphos-
phate-glucuronyltransferase (UGT). These
results will now be discussed brieﬂy. 
CYP enzymes catalyze reactions involved
in the oxidative metabolism of xenobiotics
and steroids. Many classes of chemical car-
cinogens are bioactivated to DNA-reactive
species by P450 enzymes. Potential mam-
mary carcinogens such as polycyclic aromatic
hydrocarbons (PAHs) and aromatic amines
are activated to reactive species by P450
1A1. Several CYP1A1 variants have been
studied. For example, the MspI polymor-
phism may be a significant risk factor for
breast cancer in Chinese women in Taiwan
(21). However, in a case–control study
nested within the Nurses’ Health Study,
no increase was associated with variant
CYP1A1 genotypes (22). CYP1A1 expres-
sion is highly variable, independent of the
genetic polymorphism: over a 400-fold
difference was noted in 58 samples of non-
tumor breast tissue (23).
P450 1B1 bioactivates carcinogens and
hydroxylates 17β-estradiol at the C-4 posi-
tion, forming genotoxic 4-hydroxyestradiol
(24). Identified polymorphisms of human
CYP1B1 include codon 119 Ala→Ser and
codon 432 Val→Leu. Epidemiologic associ-
ations of these variants with breast cancer are
still controversial (25),(26).
GST enzymes, which inactivate reactive
electrophilic intermediates by catalyzing glu-
tathione conjugation, are important enzymes
in the detoxication of chemical carcinogens.
In humans, the GST gene superfamily is
divided into at least four classes: alpha
(GSTA), mu (GSTM), pi (GSTP), and theta
(GSTT). Only about half the population car-
ries the GSTM1 gene (27). The GSTM1 null
genotype has been associated with increased
risk of breast cancer in a South Korean study
population (28) but not in an Australian
Caucasian population (29). Meta-analysis of
46 studies found a slight increase in risk of
breast cancer among postmenopausal women
with the GSTP1 Ile→Val polymorphism and
the GSTM1 deletion (30).
COMT catalyzes the methylation of
endogenous catechol compounds such as
biogenic amines (dopamine) and catechol
estrogens (2- and 4-hydroxyestrogens).
Variations in COMT activity will affect the
bioavailability of endogenous estrogens. The
low-activity COMT allele may contribute to
both the risk (31) and progression (32) of
breast cancer.
N-Acetyltransferases (encoded by the
human  NAT1  and  NAT2  genes) are
involved in both the bioactivation and the
detoxication of aromatic amines (33). These
enzymes possess three activities: N-acetyla-
tion, O-acetylation, and N,O-acetyltransfer
activity. The O-acetylation and N,O-acetyl-
transfer activities can lead to formation of
unstable acetoxy compounds that decom-
pose to DNA-reactive nitrenium ions. The
classic NAT2 polymorphism accounts for
slow versus fast acetylation of drugs such as
isoniazid. About half of individuals in
Caucasian populations are slow acetylators;
Inuit and Oriental populations are predomi-
nantly fast acetylators (up to 90%). The
controversial question of NAT1 and NAT2
associations with breast cancer will be dis-
cussed later in this review.
SULT and UGT catalyze conjugation of
endogenous compounds and xenobiotics to
form sulfates and glucuronides, respectively.
Human mammary tissue expresses SULT
(34) and UGT (35) activities, and the roles
of polymorphisms of the genes encoding
these enzymes in breast cancer are now
under investigation (35,36).
Demographics of
Breast Cancer
Studies of migrant populations and geo-
graphic variations in incidence of breast can-
cer suggest that lifestyle and environmental
inﬂuences are involved in the etiology of the
disease. The rates of breast cancer in Asian
and Mediterranean countries are signifi-
cantly lower than in North America (37),
yet, within several generations, the rate of
breast cancer in female offspring of Asian
immigrants to the United States approaches
the American rate (38). Recent studies indi-
cate that the rate of breast cancer in Japan is
increasing, coincident with the westerniza-
tion of the Japanese lifestyle (39). Generally,
the incidence of breast cancer in American
Indian and Alaskan Native women has been
lower than in most of the other racial/ethnic
groups in the United States. Migration of
these Native American families has led to an
increase in the breast cancer rates. An ele-
vated incidence of breast cancer has been
noted in the U.S. northeast, especially the
New York–New Jersey–Pennsylvania area
(40), which is among the most heavily pol-
luted regions on the continent in terms of
industrial and vehicular emissions. An
increased risk of breast cancer was also
reported for postmenopausal women who
lived for more than 10 years near an indus-
trial facility in Long Island, New York (41).
Cigarette Smoking and 
Breast Cancer
Tobacco smoke is the major causative agent
in the development of lung cancer (42). In
contrast, the possible role of smoking in
breast cancer has remained controversial. A
large number of epidemiologic studies were
conducted during the 1980s and early
1990s. Several found a weak association of
smoking with breast cancer, many found no
difference in risk, and a few even noted
reduced risk. Reduced risk might be
accounted for on the basis of an antiestro-
genic effect of smoking, lowering the age of
menopause and total exposure to estrogen.
In these early studies, analyses were generally
conducted with respect to never-smoker and
ever-smoker categories.
During the last 10 years, the effect of
environmental tobacco smoke (ETS) (also
referred to as secondhand smoke or side-
stream smoke) on human health has become
an important public health issue. Some
recent epidemiologic studies have divided
never smokers into unexposed nonsmokers
and passive smokers (individuals exposed to
ETS). A groundbreaking Swiss study care-
fully examined the relationship between
tobacco smoke exposure and breast cancer
(43). In the population-based case–control
study, women were categorized as active
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nonsmokers. An active smoker was defined
as a woman who had smoked at least 100
cigarettes in her lifetime, whereas a passive
smoker was any woman exposed to passive
smoke for at least 1 hr per day for at least 12
consecutive months during her lifetime.
Among ex-active and current active smokers,
an increase in the risk of breast cancer was
associated with the number of cigarettes
smoked per day. The odds ratio (OR) of
breast cancer in current active smokers
ranged from 1.5 (95% [conﬁdence interval]
CI 0.6–3.9) for women who smoked 1–9
cigarettes per day and 2.1 (95% CI 0.9–4.8)
for women who smoked 10–19 cigarettes
per day, to 5.1 (95% CI 2.1–12.6) for
women who smoked more than 20 cigarettes
per day. The OR of breast cancer in passive
smokers was 3.2 (95% CI 1.7–5.9). It was
estimated that exposure to passive smoke for
2 hr per day for 25 years was equivalent to
actively smoking 20 cigarettes per day for 20
years. A similar contribution of ETS to dis-
ease development has also been observed in
heart disease (44).
In a recent Canadian study, data from
2,317 cases of breast cancer (25% pre-
menopausal and 75% postmenopausal
women) and 2,438 population controls were
analyzed for risk of breast cancer with passive
and active (current and ex-) smoking (45).
When the data were analyzed without con-
trolling for passive smoke exposure, with
never smokers as the referent group, the OR
values for breast cancer were 1.0 (95% CI
0.8–1.3) and 1.2 (95% CI 1.0–1.4) for
ex-smokers/current smokers in premeno-
pausal and postmenopausal women, respec-
tively. When the referent group included only
women who never actively smoked, never
lived with a regular smoker for at least 1 year,
and never worked for at least 1 year with reg-
ular smokers, the results were very signiﬁcant.
For the same cohort of premenopausal
women, the OR values were 2.3 (95% CI
1.2–4.6) for passive smokers, 2.6 (95% CI
1.3–5.3) for ex-smokers and 1.9 (95% CI
0.9–3.8) for active smokers. For post-
menopausal women, the effects of ETS were
also observed; the OR values were 1.2 (95%
CI 0.8–1.8) for passive smokers, 1.4 (95% CI
0.9–2.1) for ex-smokers, and 1.6 (95% CI
1.0–2.5) for active smokers.
The gene–environment interaction for
tobacco smoke has also been investigated. In
1996 it was reported that postmenopausal
women who were slow acetylators and
smoked have a significantly elevated risk of
breast cancer (OR up to 4.4) (46). This
result could not be confirmed in a nested
case–control study in the Nurses’ Health
Study (47). On the other hand, Millikan et
al. (48) reported that postmenopausal
women who smoked within the past 3 years
and possessed the rapid NAT2 genotype
(OR = 7.4; 95% CI 1.6–32.6) had a greater
risk of breast cancer than women with the
slow NAT2 genotype (OR = 2.8; 95% CI
0.4–8.0). Morabia and colleagues (49) inves-
tigated the role of active and passive smok-
ing, this time including the interaction of
the NAT2 genotype. The increased risk of
breast cancer was observed only in post-
menopausal women, not premenopausal
women. Fast acetylators who passively
smoked had a greater risk (OR = 11.6; 95%
CI 2.2–62.2) than fast acetylators who
actively smoked (OR = 8.2; 95% CI
1.4–46.0). The effect of smoking was
observed with slow acetylators, but the asso-
ciation was weaker: passive smokers (OR =
1.1; 95% CI 0.3–4.3), active smokers (OR =
2.9; 95% CI 0.8–11.2). The previously
mentioned nested case–control study in the
Nurses’ Health Study also analyzed two
genetic variants of CYP1A1 (22). A modest
increase of risk was observed among women
who started smoking before the age of 18
and possessed the CYP1A1 MspI variant
(T´C transition at nucleotide 6235) or
another CYP1A1 variant, the exon 7 poly-
morphism (A´G transition at nucleotide
4889). No more than a small percentage
(<5%) of all cases of breast cancer can be
attributed to these two risk factors. 
Breast Cancer and Lifestyle
Factors Other Than Smoking;
Dietary Factors
The relationship of alcohol consumption to
risk of breast cancer has been studied for
many decades (50,51). Low consumption
levels (1–3 drinks per week) were not found
to increase risk of breast cancer (52). The
only significant increase of relative risk
(1.41–1.70) compared with nondrinkers is
associated with high levels of intake, at least
60 g/day (approximately 2–5 drinks) (53,54).
Alcohol consumption may increase levels of
plasma estrogen and insulinlike growth fac-
tors (55,56). An increased risk of breast can-
cer was observed recently in postmenopausal
women who consumed alcoholic beverages
and had low folate intake (57,58).
Dietary fat has often been examined as a
risk factor for breast cancer (59). Although
the question remains controversial, the con-
sensus indicates that there is not a strong
association between fat intake during adult-
hood and risk of breast cancer. The roles of
dietary fat intake during childhood and ado-
lescence, and of different types of dietary
fatty acids, remain unclear.
Meat consumption is a major source of
dietary fat. In addition, genotoxic substances
are formed during the cooking or processing
of meat. A case–control study in Uruguay in
1996 found an increased risk of breast cancer
with intake of red meat (60). A later study
found a positive correlation between con-
sumption of well-done meat and risk of
breast cancer (61). Two classes of carcino-
genic compounds can be formed in the
grilling of meats: PAHs and heterocyclic aro-
matic amines (62). PAHs are formed from
the pyrolysis of fats during charcoal grilling
and are deposited on the meat by smoke
from the fat dripping onto the coals of the
grill. The presence of PAH–DNA adducts in
human breast tissue (63) is consistent with
involvement of these compounds in breast
cancer, but epidemiologic evidence in this
regard is very limited. Mutagenic heterocyclic
aromatic amines (discussed in more detail
later in this chapter) are formed by various
high-temperature cooking methods, includ-
ing broiling, frying, roasting, and barbecuing. 
Diets with ﬁve or more daily servings of
fruits and vegetables may be protective
against breast cancer (64), but a later study
did not support a protective role for dietary
fruits and vegetables in adulthood (65). An
inverse association between dietary folate
intake and breast cancer risk was observed in
the Shanghai Breast Cancer Study (66).
Consumption of fruits and vegetables rich in
α-carotene, β-carotene, vitamin A, vitamin
C, and lutein/zeaxanthin is a protective fac-
tor reducing risk of breast cancer in pre-
menopausal women, including women with
family history of breast cancer (67). In an
earlier study, another vitamin, α-tocopherol,
was suggested to be a protective factor for
premenopausal women with family histories
of breast cancer (68).
Occupation and Risk of
Breast Cancer
The participation of women in the work
force has increased steadily since the 1950s.
Research on occupational exposure to car-
cinogens has focused predominantly on the
male worker. Only recently has there been
special interest in occupational exposure to
hazardous agents as a factor in the risk of
breast cancer in women (69,70). Women
exposed to benzidine or β-naphthylamine
while employed in a dye factory in Moscow
had approximately double the risk of breast
cancer (71). Labreche and Goldberg (72)
have examined occupational exposure to
organic solvents. The solvents benzene, 1,1-
dichloroethane, 1,2-dichloroethane, 1,2-
dichloropropane, and dichloromethane are
rodent mammary carcinogens and may be
encountered in the petrochemical, dry clean-
ing, shoe manufacturing, and chemical
industries. There is evidence for a positive
association of several occupations with risk
of breast cancer, including nurses, teachers,
laboratory technicians, dental hygienists,
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workers (73–75). The high incidence
among professional workers has been partly
attributed to reproductive history, including
nulliparity and full-term pregnancy at a later
age (76).
Estrogenic chemicals represent another
possible occupational chemical hazard
(77,78). Occupations and potential expo-
sures include nursing and medicine (nonyl-
phenol, bisphenol A, butyl benzyl phthalate);
food handlers (butylated hydroxyanisole);
electronic industry (bisphenol A); gasoline
service station workers; assembly workers;
and machine operators (4-octylphenol).
Potential exposure to polychlorinated
biphenyls (PCBs) was limited to assembly
jobs in the electrical equipment industry and
clinical/laboratory personnel. Despite these
potential exposures, there is little direct evi-
dence that occupational exposures to xeno-
estrogens are signiﬁcant hazards.
A recent Danish study found an elevated
risk of breast cancer in males with occupa-
tional exposure to gasoline and vehicular
exhaust (79). This elevated risk increased to
an OR of 5.4 in men who were younger
than 40 years when ﬁrst employed in a trade
with this type of exposure. The authors pro-
posed that benzene, 1,3-butadiene, 1,2-
dibromoethane, and 1,2-dichloroethane,
which are found in gasoline, as well as PAHs
in the combustion residue may be involved
in the etiology, as they are rodent mammary
carcinogens.
Breast Cancer and
Organochlorine Pollutants
Causal links between breast cancer and spe-
ciﬁc environmental pollutants have frequently
been proposed (80–83) but remain very con-
troversial. Organochlorine pesticides and
related compounds that have been implicated
in breast cancer include DDT (bis(4-chloro-
phenyl)-1,1,1-trichloroethane) and its major
metabolite DDE (bis(4-chlorophenyl)-1,1-
dichloroethene; chlordane; dieldrin; benzene
hexachloride (including γ-lindane); and
PCBs. These organic chemicals have long bio-
logic half-lives (up to 12 years) (84) and
bioaccumulate in adipose tissue, including the
breast. DDT has been widely used as an
insecticide throughout the world but has been
banned in the United States since 1972.
Several preliminary case–control studies
found elevated levels of DDT and DDE in
breast lipid or blood serum from breast cancer
patients (85–88), and these reports height-
ened public suspicion of a relationship
between pesticide exposure and incidence of
breast cancer. However, recent reports
(including those from the authors of the origi-
nal studies) have concluded that exposure to
DDT or DDE during adulthood is not asso-
ciated with an increased risk of breast cancer
(89–98). Research into the relationship
between pesticides and risk of breast cancer
has recently been reviewed in these pages (99).
The xenoestrogen hypothesis proposes
that environmental pollutants that possess
estrogenic activity stimulate breast cell
proliferation and thereby induce or promote
breast cancer (100,101). Environmental
estrogen mimics are also implicated as
endocrine disruptors in wildlife species.
Although there is experimental evidence on
the estrogenicity of several chlorinated pesti-
cides (including DDT), as mentioned above,
recent epidemiologic studies find no
increased risk of breast cancer with pesticide
exposure (102–104). Furthermore, in view
of the presence of natural hormone and
antihormone mimics in our diet, Safe and
Zacharewski (105) concluded that the estro-
genic contribution of organochlorine
compounds is small and their role in devel-
opment of breast cancer is questionable. The
role of other xenoestrogens, such as alkyl-
phenols and phthalates, which are used in
the synthesis of detergents, plastics, and
polymers, is still under investigation (106).
The xenoestrogen hypothesis has been exten-
sively debated in other fora and we will not
extend the discussion in this review.
Aromatic Amines as
Mammary Carcinogens
Many aromatic amines are of toxicologic
concern to humans (Figure 1). Occupational
exposure began with the dye industry in the
nineteenth century and continues today in
the plastic and chemical industries. The gen-
eral population can be exposed to various
aromatic amines through environmental pol-
lution, tobacco smoke, medicine, and diet.
The chemical class of aromatic amines can
be subdivided into monocyclic, polycyclic,
and heterocyclic amines. Most heterocyclic
amines, many polycyclic aromatic amines,
and some monocyclic aromatic amines are
bacterial mutagens. Several polycyclic aro-
matic amines, such as benzidine, 4-amino-
biphenyl, and β-naphthylamine, have been
classified by the International Agency for
Research on Cancer as known human car-
cinogens. Epidemiologic studies have sug-
gested that monocyclic aromatic amines
such as o-toluidine (2-methylaniline) and
4-chloro-o-toluidine are also human car-
cinogens (107,108). Comprehensive animal
bioassays have determined that many
aromatic amines are rodent carcinogens pro-
ducing tumors at various sites including the
mammary gland (109). We have detected
environmental aromatic amines, including
o-toluidine, a rat mammary carcinogen, in
human milk samples from smoking and
nonsmoking mothers (110). This indicates
that the ductal epithelial cells of the breast
are exposed to aromatic amines. We and
others have continued to investigate the eti-
ologic role of aromatic amines in breast
cancer and have focused on the dietary
heterocyclic amines.
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Figure 1. Structures of aromatic and heterocyclic amines.
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Twenty-five years ago, Sugimura and
colleagues found that organic extracts from
grilled fish are potently mutagenic in the
Ames/Salmonella mutagenicity assay (111).
From various grilled meat extracts and model
systems, approximately 20 mutagenic hetero-
cyclic amines have since been isolated and
characterized. The genotoxicity of these com-
pounds has also been demonstrated in cul-
tured mammalian cells with various end
points, including mutagenesis and induction
of chromosome aberrations, sister-chromatid
exchanges, DNA strand breaks, and DNA
repair synthesis. These food pyrolysis prod-
ucts have been detected in grilled/broiled/
fried beef, pork, chicken, lamb, and ﬁsh, with
levels ranging from <0.1 to >300 ng/g (ppb).
The most abundant heterocyclic amines in a
typical Western diet are 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP); 2-amino-3,8-dimethylimidazo[4,5-
f]quinoxaline (MeIQx); 4,8-2-amino-3,4,8-
trimethylimidazo[4,5-f]quinoxaline
(diMeIQx); 2-amino-3-methylimidazo[4,5-
f]quinoline (IQ); and 2-amino-α-carboline
(ΑαC) (112). PhIP, 4,8-diMeIQx, and
MeIQx account for ~60% of the total muta-
genic activity of a fried beef sample (113).
In general, higher cooking temperatures
and longer cooking times increase the concen-
tration of heterocyclic amines, whereas mari-
nating the meat decreases the concentration
of some heterocyclic amines (114,115).
Higher levels are found in grill scrapings,
meat drippings, and pan residues (116). Some
heterocyclic amines can be detected in the
cooking fumes (117,118). In contrast, the
cooking of meats by stewing, poaching, or
microwaving does not lead to the formation
of heterocyclic amines.
In addition to dietary exposure, hetero-
cyclic amines have been detected, at very low
concentrations (ppt), in environmental sam-
ples, including indoor and ambient air
(0.07–0.34 pg/m3), river water, rainwater
(0.13–84.7 ng/L), municipal waste water,
cigarette smoke (0.02–47.8 ng/cigarette),
smoke from the combustion of wood chips
(2.26 ng/g) and rubber (0.15–1.98 ng/g),
and diesel-exhaust particles (0.01–14.1
pg/mg) (119–121).
Most heterocyclic amines are hepato-
carcinogens in rodents and mammary car-
cinogens in female rats (122). PhIP induces
colon cancers in male rats, mammary cancers
in female rats, and lymphomas in mice of
both sexes. The incidence of mammary can-
cer reached 47% in female F344 rats receiv-
ing a diet containing 400 ppm PhIP for 52
weeks (123). PhIP induces mammary tumors
in female Sprague-Dawley rats in a dose-
dependent manner (124). Young female
Sprague-Dawley rats treated with PhIP
(75 mg/kg/day, po) for 2 weeks and then
placed on a high-fat diet had a higher inci-
dence of tumor formation than rats on a low-
fat diet (125). Snyderwine has suggested that
the rat model of a high-fat diet in conjunc-
tion with a food-derived carcinogen parallels
the increased risk of breast cancer in women
who are exposed to heterocyclic amines and
high levels of fat through the consumption of
cooked meats (126).
Assessment of Dietary Exposure
to Heterocyclic Amines
Human dietary exposure to heterocyclic
amines has been calculated by various meth-
ods. From the levels of compounds detected
in the urine, it was estimated that a Japanese
study group ingested 0.2–2.6 µg MeIQx and
0.1–13.8 µg PhIP daily (127,128). Other
studies have calculated the exposure from
the intake of meat, as recorded in question-
naires. Databases have been constructed for
estimation of the levels of heterocyclic
amines in various types of meat according to
the cooking method, temperature, and time.
In examining the cancer risk of heterocyclic
amines, Layton et al. (129) estimated that
the typical U.S. diet entails total heterocyclic
amine intake of 1.4 µg/day for a 54-kg indi-
vidual. The rank order of the five most
abundant heterocyclic amines consumed is
PhIP > AαC > MeIQx > diMeIQx > IQ,
whereas the order of carcinogenic potencies
of the same group is almost the reverse: IQ >
diMeIQx > MeIQx > PhIP > AαC. Based
on this study, the greatest incremental risk of
cancer through consumption of meats and
ﬁsh is due to PhIP. 
Augustsson et al. (130) estimated that
the elderly Swedish population consumes a
total of 160 ng heterocyclic amines per day,
with the order of the intake PhIP ~ MeIQx
> diMeIQx >> 2-amino-2,4-dimethylimi-
dazo[4,5-f ]quinoline (MeIQ) ~ IQ. The
estimated dietary intake for New Zealanders
who had a general preference for medium to
well-done roasted and baked meat and fish
was 1 µg heterocyclic amines per day (131).
The role of diet in breast cancer risk was
discussed earlier. Here we consider specific
studies of the hazard presented by intake of
meat and associated heterocyclic amines.
Several epidemiologic studies found an
increased risk of breast cancer among women
who consumed meat often (132–134). More
recent studies have looked speciﬁcally at con-
sumption of well-done meat and heterocyclic
amine exposure. Women who usually con-
sumed very well-done red meat had 4.6-fold
increased risk of breast cancer compared with
those who usually ate meat that was rare or
medium (135). The increased risk of breast
cancer has been correlated with exposure to
PhIP but not to MeIQx or diMeIQx (136). 
The possible role of NAT polymor-
phisms has also been investigated. Several
studies that assessed meat intake and esti-
mated heterocyclic amine exposure found
that NAT2 genotype, alone or with these
factors, was not associated with increased
risk of breast cancer (137–139). However,
the latest study found a significant
dose–response relationship between risk of
breast cancer and consumption of well-done
meat among women with rapid/intermediate
NAT2 genotype (140). The product of the
NAT1 gene is a mammary enzyme capable
of bioactivating heterocyclic amines.
Women who possessed the NAT1*11 allele
(1.2–3.6% frequency) and consumed high
levels of red meat or well-done meat had a 6-
fold increase in risk of breast cancer (141). 
Heterocyclic amine exposure through
intake of well-done meats is a biologically
plausible risk factor for breast cancer.
Epidemiologic studies usually estimate hete-
rocyclic amine exposure from meat intake, as
reported in questionnaires, and evaluate
recent dietary practices. The period between
menarche and first full-term pregnancy,
when rapid mammary cell division occurs,
may be most critical for the initiation of
breast carcinogenesis (142). Therefore, hete-
rocyclic amine intake during adolescence
and early adulthood may be most signiﬁcant
in development of breast cancer. Other pos-
sible criticisms of the questionnaire-
estimated heterocyclic amine levels include
recall bias and lack of validation with a bio-
marker of exposure (e.g., DNA or protein
adducts) (143).
Biologic Monitoring of Heterocyclic
Amine Exposure
The bioavailability of heterocyclic amines
from the consumption of cooked meat has
been demonstrated through the detection of
the compounds in the urine, as mentioned
earlier (Tables 1 and 2). Urinary heterocyclic
amine levels can typically range from 0.01 to
78 pg/mL (144,145) (Table 1). None of
these compounds was detected in the urine
of colon cancer patients receiving parenteral
alimentation (127), which indicates that uri-
nary excretion reﬂects recent dietary intake.
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Table 1. Levels of heterocyclic amines in human
urine reported in the literature. 
Heterocyclic amine pg/mL Reference
MeIQx 10.6–17.8a (144)
Trp-P-1 0.2–0.60b (127)
Trp-P-2 0.2–0.57b
PhIP 0.10–1.66b
MeIQx 0.01–37.0b
PhIP 5.6–17a (145)
MeIQx 9–78a
aMean concentration in 12-hr urine samples. bMean con-
centration in 24-hr urine samples. The majority of ingested PhIP (and other
heterocyclic amines) undergo metabolism in
the liver, followed by urinary excretion as
conjugated products. N2-hydroxy-PhIP-N2-
glucuronide is the major urinary metabolite.
Other metabolites detected include PhIP-N2-
glucuronide, PhIP-4´-sulfate, and N2-
hydroxy-PhIP-N3-glucuronide, and large
differences in the percentages of the metabo-
lites are seen within and between various
study groups (Table 2). The individual varia-
tion in the ratio of the urinary metabolites of
PhIP suggests that there is differential expres-
sion of xenobiotic-metabolizing enzymes,
possibly because of disease state, medication,
environmental chemical exposure, gender, or
genetic polymorphisms.
Although protein (in particular, hemo-
globin [Hb]) adducts of monocyclic and
polycyclic aromatic amines have been used
as biomarkers of exposure for the last 20
years, the comparable use of serum albumin
and Hb adducts of heterocyclic amines has
been delayed because of the very low levels
of binding. Studies have been conducted in
which cancer patients ingest a single dose of
[14C]-MeIQx (either 21.3 µg, equivalent to
the amount of MeIQx ingested from food
sources over 1 week, or 228 µg) (146) or
[14C]-PhIP (147) (70 µg; equivalent to eat-
ing 175 g of very well-done grilled chicken).
Very low levels of binding to albumin (0.13
or 1.8% of the dose) and Hb (0.05 or
0.26% of the dose) have been detected by
accelerator mass spectrometry (AMS). In a
recent report (148), blood samples from 35
Italian volunteers were analyzed for steady-
state levels of PhIP protein adducts. By liq-
uid chromatography/MS/MS analysis of the
acid-hydrolyzed protein, approximately half
the samples had detectable PhIP-serum albu-
min adducts (5.2 ± 1.3 fmol/mg protein)
and PhIP-Hb adducts (2.3 ± 0.6 fmol/mg
protein) but not necessarily both. Only 6
individuals, all of whom were vegetarians,
had neither albumin nor Hb adducts.
Heterocyclic Amines as Human
Mammary Carcinogens: Mechanisms 
The majority of invasive breast cancer is ini-
tiated in the mammary ductal epithelial cells.
The formation of DNA adducts is a critical
step in the cancer initiation process. Most
carcinogens, including heterocyclic aromatic
amines, require metabolic activation to form
reactive electrophilic species that can cova-
lently bind to nucleophilic sites of DNA
bases. With PhIP, for example, hepatic P450
1A2 [or mammary P450 1A1 and 1B1
(149)] can catalyze N-hydroxylation of the
exocyclic amino group to yield N2-hydroxy-
PhIP. In the liver, as well as in extrahepatic
tissues, esteriﬁcation can occur, catalyzed by
various phase II enzymes. O-Acetylation or
O-sulfation produces unstable products that
yield highly reactive arylnitrenium ions. The
C-8 guanine adduct has been observed as the
major DNA adduct, with the N2-guanine
adduct detected less frequently (150,151).
To be mammary carcinogens, the reactive
species of the heterocyclic amine must reach
the genetic material of the mammary
epithelial cells.
Over 15 years ago, it was reported that
the DNA from the breast tissue of cancer
patients displayed signiﬁcantly higher levels
of unidentiﬁed adducts than DNA from the
tissue from healthy controls (152,153).
From the analysis of the 32P-postlabeling
DNA adducts, it was suggested that environ-
mental chemicals, including tobacco smoke
and PAHs, are responsible for many of the
adducts. Using 32P-postlabeling analysis,
DNA adducts of heterocyclic amines were
detected in the mammary gland 6 hr after
lactating rats were treated with a single dose
of MeIQ, IQ, or PhIP (154). Moreover, the
PhIP-DNA adduct levels were higher than
MeIQ- or IQ-DNA adduct levels, and the
PhIP-DNA adduct levels were approxi-
mately 15-fold higher in the mammary
gland than in the liver.
PhIP-DNA adducts, ranging from
26–477 adducts/1012 nucleotides as detected
by AMS, have been detected in the normal
and tumor breast tissue of cancer patients
(155). Although the mammary epithelial
cells are the cellular targets of tumorigenesis,
both mammary epithelial cells and mam-
mary ﬁbroblasts can metabolize IQ to DNA-
binding species (156). The fibroblast may
activate the heterocyclic amines to species
that are then transferred into the adjacent
epithelial cells.
Human milk, extracted by methods for
isolation of heterocyclic amines, yielded
samples that were mutagenic in the Ames
assay with TA1538 and YG1019, induced
micronucleus formation in MCL-5 cells, and
caused single-strand DNA breaks in MCL-5
and exfoliated mammary cells (157). Eleven
of 20 milk samples examined were positive in
the Ames assay with Salmonella typhimurium
strain YG1019 (a strain sensitive to aromatic
amines). In another study, PhIP, 3-amino-1-
methyl-5H-pyrido[4,3-b]indole (Trp-P-2), o-
toluidine, and p-chloroaniline were activated
to DNA-damaging species by exfoliated
breast milk cells from various donors (158). 
Recently, the bioavailability of PhIP to
the breast tissue was demonstrated by giving
a dietary equivalent dose of [14C]-PhIP in a
gelatin capsule to breast cancer patients
before surgery (155). Within 4–6 hr,
radioactivity was detected in both normal
and tumor breast tissue, and DNA adducts
were found in both tissue types. PhIP is
rapidly distributed to the breast tissue and
bioactivated to DNA-reactive species within
this short time frame.
We recently examined the levels of PhIP
in the milk of healthy lactating women
(159). The analysis showed 9 of 11 samples
to be contaminated with PhIP, ranging from
13 to 59 pg/mL. These levels are comparable
to the amounts of unmetabolized PhIP
excreted into urine, as reported in previous
studies. No PhIP was detected in the milk of
a single vegetarian donor. [Various compo-
nents of vegetarian diets may affect breast
cancer risk (160).] Thus, PhIP is absorbed
into the body (most likely from the ingestion
of PhIP-containing cooked meat), is distrib-
uted to the mammary gland, and is subse-
quently excreted into the milk. As PhIP is
formed by heating creat(in)ine with amino
acids, animal meat is the most likely source.
From the circulating blood in the breast,
PhIP must be transferred across the ductal
mammary epithelial cells into the milk in the
lumen of the lobules, which empty into the
ductal system. Thus, the mammary epithe-
lial cells are directly exposed to PhIP.
Furthermore, mammary epithelial cells can
bioactivate PhIP to reactive genotoxic species. 
PhIP is transferred via the milk of mice
and rats to their offspring (161–164).
Unmetabolized PhIP is transferred in a lin-
ear dose-dependent manner into the milk of
rats treated with PhIP (0.05–5.0 mg/kg iv)
(161). PhIP is rapidly cleared from the body;
with the lowest dose, PhIP was detected in
the blood and milk after 1 hr, and after 4 hr,
PhIP was detected only in the milk. The
mean milk-to-plasma ratios, at 1 hr for the
lowest dose and at 4 hr for the highest dose,
were 9.4 and 9.3, respectively. This suggests
a high degree of transfer of PhIP into the
milk. Female offspring of rats exposed to
PhIP during the gestation and lactation
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Table 2. The variation in urinary excretion of PhIP metabolites in two study groups.
Percentage of total metabolites
Three elderly male  Eight healthy 
PhIP metabolite colon cancer patientsa female volunteersb
N 2-OH-PhIP-N 2-glucuronide 47–61 47–88
PhIP-N 2-glucuronide 4.34–7.8 10–45
PhIP-4´-sulfate 5.8–12.4 ~1–7
N 2-OH-PhIP-N3-glucuronide 7.79–11.6 ~1–3
aOral dose of 70–80 µg [14C]PhIP in a gelatin capsule. Data from Kulp et al. (170). bIngested a well-done chicken breast
containing 19 or 21 µg PhIP. Data from Malfatti et al. (171).periods only showed a higher incidence of
mammary carcinomas than control rats with
no exposure (163). The lactating rats were
treated with 10 mg PhIP/kg body weight;
the pups nursed for a 3-week period. This
dose is 400,000 times the estimated human
exposure of 25 ng total heterocyclic
amines/kg body weight (129). It is not yet
known whether breast-fed infants would
incur any deleterious effects from this low-
level heterocyclic amine exposure. The
metabolism of PhIP and other heterocyclic
amines has not been fully characterized in
humans. However, striking differences in the
metabolism of MeIQx and PhIP between
rodent models and humans have been found
(165). A new metabolite, 2-amino-3-
methylimidazo-[4,5-f ]-quinoxaline-8-car-
boxylic acid (IQx-8-COOH) is formed only
by human P4501A2-catalyzed reactions
(166). Glucuronidation of N-OH-PhIP by
rat liver microsomes forms predominantly
N-OH-PhIP-N 3-glucuronide, whereas
human liver microsomes forms predomi-
nantly N-OH-PhIP-N2-glucuronide (167).
PhIP and its metabolites PhIP-4´-sulfate, 4´-
hydroxy-PhIP, and N2-hydroxy-PhIP-N3-
glucuronide were detected in the milk of
lactating rats (164) (Figure 2). The metabo-
lites in human milk have not yet been deter-
mined, but possible major candidates
include PhIP-4´-sulfate and N-OH-PhIP-
N2-glucuronide.
Because our exposure to the heterocyclic
aromatic amines is chieﬂy dietary, reduction
in the intake of cooked meats and avoidance
of very well-done meats can minimize expo-
sure. The induction of mammary carcinomas
by PhIP in female rats was signiﬁcantly inhib-
ited by the coadministration of chlorophyllin
or a synthetic antioxidant (168), and PhIP-
DNA adduct formation in the mammary
epithelial cells was lower in rats receiving
green tea instead of regular drinking water
(169). Thus, it may be possible to reduce the
genotoxic effects of heterocyclic amines with
the concurrent intake of food and drink high
in antioxidants or chlorophyllin.
Further clarification of the significance
of specific environmental exposures to
mammary carcinogens by epidemiologic,
molecular epidemiologic, and biologic
analysis may lead to progress in the primary
prevention and chemoprevention of human
breast cancer.
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